TKNO (TKNO) revenue breakdown
By product, Lab Essentials is the largest at 77% of fiscal 2025 revenue; Clinical Solutions grew fastest, 10% a year over 5 years.
By region, United States is the largest at 94% of fiscal 2025 revenue; International grew fastest, 14% a year over 5 years.
Revenue by product
Fiscal years, as TKNO reports them in its 10-K filings; fiscal 2025 total $41M.
| Products | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|
| Lab Essentials | $21M | $27M | $32M | $29M | $29M | $31M | 77% |
| Clinical Solutions | $5M | $7M | $8M | $7M | $7M | $8M | 19% |
| Other | $953,000 | $1M | $1M | $1M | $2M | $2M | 5% |
| Sample Transport | $4M | $2M | — | — | — | — | — |
Revenue by region
Fiscal years, as TKNO reports them in its 10-K filings; fiscal 2025 total $41M.
| Regions | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|
| United States | $30M | $36M | $40M | $35M | $36M | $38M | 94% |
| International | $1M | $1M | $1M | $2M | $2M | $2M | 6% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for TKNO.
Open TKNO in InvestinglyQuestions
Where does TKNO make its money?
In fiscal 2025, by product: Lab Essentials $31M, Clinical Solutions $8M, Other $2M.
From TKNO's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.